Findings to showcase the promise of company’s ‘Macrophage Conditioning’ approach in reversing immunosuppression within acidic tumour microenvironment and driving anti-tumour activity.
OXFORD, UK – November 3, 2022
Pathios Therapeutics Limited (“Pathios”), a biotech company focused on the development of first-in-class therapies for cancer, today announced that new preclinical data highlighting the therapeutic potential of the company’s novel GPR65 inhibition platform will be the focus of a poster presentation at the upcoming 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2022). Presented results will showcase the company’s unique approach to “macrophage conditioning” with novel GPR65 inhibitors as a means to reversing the immunosuppression that results from an acidic tumour microenvironment, and, in turn, driving anti-tumour activity. SITC 2022 is being held November 8-12, 2022, in Boston, Massachusetts.
Details of the company’s presentation at SITC 2022 are as follows:
Poster Presentation #1324:
- Title: Inhibition of Acid Sensing by GPR65 Normalizes Gene Expression in Macrophages, Increases Immune Cell Infiltration in Tumours, and Restrains Subcutaneous MC38 Growth in Mice
- Presenting Author: Alastair Corbin, DPhil, senior scientist at Pathios
- Date/Time: Friday, November 11, 2022, 9:00 a.m. – 8:30 p.m. Eastern Time
- Location: Poster Hall C
Additional information on the 37th Annual Meeting of SITC is available through the conference website at: https://www.sitcancer.org/2022/home
About Acidity in the Tumour Microenvironment
The acidic tumor microenvironment, inherent to many cancers, causes a profound immunosuppression of infiltrating immune cells. This environment disarms the anti-cancer immune response and negates the effectiveness of current immunotherapies. This is particularly evident in tumour associated macrophages (TAM), where acidity is sensed by the cell-surface receptor GPR65, leading to the widespread suppression of a host of pro-inflammatory mediators and anti-tumourigenic genes as well as the up-regulation of several tissue repair genes and angiogenic factors.
About Pathios Therapeutics
Launched in 2017, Pathios is a drug discovery and development company focused on translating innovative science into new medicines. Pathios was founded by a team of experienced biotech and pharmaceutical industry professionals, entrepreneurs and clinicians. The company is focused on developing small-molecule inhibitors of the pH-sensing G protein-coupled receptor GPR65 to target immunosuppressive macrophages in advanced cancers. To date, Pathios has secured a total of US$33M in Series A funding from the leading venture capital firms, Canaan Partners and Brandon Capital. Pathios is headquartered at the Innovation Centre on Milton Park, a key science precinct south of Oxford, UK. For more information, please visit www.pathios.com.
Contacts
Pathios Therapeutics
Stuart Hughes
Chief Executive Officer
+44 1235 644 960
info@pathios.com
Vida Strategic Partners (on behalf of Pathios Therapeutics)
Tim Brons
Executive Vice President
+1 646 319 8981
tbrons@vidasp.com